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Summary
Background—Hepatitis-related liver diseases are a leading cause of mortality and morbidity 
among people with HIV/AIDS taking combination antiretroviral therapy. We assessed the effect of 
hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection on HIV outcomes in patients in 
China.
Methods—We did a nationwide retrospective observational cohort study with data from the 
China National Free Antiretroviral Treatment Program from 2010–11. Patients older than 18 years 
starting standard antiretroviral therapy for HIV who had tested positive for HBV and HCV were 
followed up to Dec 31, 2012. We used Kaplan-Meier analysis and Cox proportional hazard models 
to evaluate survival, and logistic regression models to estimate virological failure, immunological 
response, and retention in care.
Findings—33 861 patients with HIV met eligibility criteria. 2958 (8·7%) participants had HBV 
co-infection, 6149 (18·2%) had HCV co-infection, and 1114 (3·3%) had triple infection. All-cause 
mortality was higher in participants with triple infection (adjusted hazard ratio 1·90, 95% CI 1·53–
2·37) and HCV co-infection (1·46, 1·25–1·70) than in those with HIV only, but not in those with 
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HBV co-infection (1·06, 0·89–1·26). People with triple infection were also more likely to have 
virological failure (adjusted odds ratio [OR] 1·26, 95% CI 1·02–1·56) than were those with HIV 
only, whereas the difference was not significant for those with HBV co-infection (0·93, 0·80–1·10) 
or HCV co-infection (1·10, 0·97–1·26). No co-infection was significantly associated with a 
difference in CD4 cell count after 1 year of treatment. Loss to follow-up was more common 
among participants with triple infection (OR 1·37, 95% CI 1·16–1·62) and HCV co-infection 
(1·30, 1·17–1·45), but not HBV co-infection (0·93, 0·82–1·05), than among those with HIV only.
Interpretation—Screening for viral hepatitis is important in individuals diagnosed as HIV 
positive. Effective management for viral hepatitis should be integrated into HIV treatment 
programmes. Long-term data are needed about the effect of hepatitis co-infection on HIV disease 
progression.
Funding—The National Center for AIDS/STD Control and Prevention, China Center for Disease 
Control and Prevention.
Introduction
HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) contribute substantially to the 
global burden of disease.1,2 Worldwide, an estimated 31·4–35·9 million people have HIV/
AIDS, 350–400 million people have HBV, and 150–170 million have HCV.3–5 These viruses 
share routes of transmission and many people with HIV are co-infected with HBV and HCV, 
especially in some populations such as injection drug users and men who have sex with men.
6–8
 The prevalence of HBV co-infection ranges from 5% to 20% and HCV co-infection 
ranges from 5% to 15% in resource-limited regions.3 In New York City, the prevalence of 
HIV and HBV co-infection is 4·5%, that of HIV and HCV co-infection is 25·0%, and that of 
triple infection (HIV, HBV, and HCV) is 1·6%.9 The transmission routes and epidemiology 
of HBV and HCV in people with HIV differ between low-income and high-income 
countries.10,11 In low-income countries, most HBV infections occur in infancy or childhood 
through perinatal transmission or close household contact, and the main route of 
transmission for HCV is unsafe injection.1,12 In high-income countries, HBV is commonly 
transmitted through sexual contact and HCV through injection drug use and sex between 
men who have sex with men.10,12
The introduction of combination antiretroviral therapy has greatly increased survival and 
decreased morbidity of people with HIV.13,14 As the life expectancy of people with HIV 
increases, chronic hepatitis-related liver diseases have become a growing concern.15,16 
Additionally, hepatitis co-infection can complicate clinical management of HIV and increase 
hepatotoxicity.17,18
HIV can accelerate hepatitis-related liver diseases.15,19 By contrast, the effect of HBV or 
HCV on HIV clinical progression, immunological response, and virological response has not 
been well established.20–22 Some researchers report that HIV and HBV co-infection 
increases the risk of virological failure and death23 and that HIV and HCV co-infection 
decreases survival.24 However, others found no effect of HBV or HCV on virological or 
immunological responses to combination antiretroviral therapy or mortality.25 Moreover, 
very few data exist for the effect of triple viral co-infection on outcomes.
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We assessed the effect of HBV and HCV co-infection on HIV clinical progression, 
virological and immunological responses, and retention in care in people with HIV receiving 
combination antiretroviral therapy in China.
Methods
Study design and participants
We did a nationwide clinical observational cohort study with data from the National Free 
Antiretroviral Treatment Program database, established and managed by the National Center 
for AIDS/STD Control and Prevention, China Center for Disease Control and Prevention 
(China CDC). The organisation, management, and workings of the database have been 
previously described.26,27 In brief, local health workers complete standardised reporting 
forms at baseline (initiation of antiretroviral therapy) and follow-up (0·5, 1, 2, and 3 months 
after initiation antiretroviral therapy, and every 3 months thereafter). Forms are entered into 
a web-based electronic data collection system and sent to the national office for data-
cleaning and analysis.28
We included participants if they were older than 18 years, treatment naive, started a standard 
treatment regimen between Jan 1, 2010, and Dec 31, 2011, and had HBV surface antigen 
and HCV antibody results recorded in the database. We included follow-up data up to Dec 
31, 2012.
Since 2002, people with HIV in China with a CD4 count of 200 cells per µL or less, total 
lymphocyte count of less than 1200 cells per µL, or WHO disease stage 3 or 4 have been 
eligible for free combination antiretroviral therapy. In 2008, the CD4 count threshold for 
treatment was increased to 350 cells per µL.29 Between 2003 and 2005, in agreement with 
WHO recommendations, the first-line HIV treatment regimen recommended in China was 
zidovudine or stavudine plus didanosine and nevirapine or efavirenz.29 After 2005, these 
regimens were gradually replaced with zidovudine or stavudine plus lamivudine and 
nevirapine. Since 2010, stavudine has been phased out and tenofovir has been introduced in 
the first-line regimen, as recommended by WHO.30
This study was approved by the Institutional Review Boards of the National Center for 
AIDS/STD Control and Prevention, China CDC in Beijing, and the Center for Global Health 
at the US CDC in Atlanta, GA, USA.
Procedures
We assessed four outcomes: survival, HIV virological response, HIV immunological 
response, and retention in treatment. We calculated survival as time from treatment initiation 
to death (all-cause and non-injury) or censoring. Patients were censored at dropout, loss to 
follow-up, or on Dec 31, 2012, whichever came first. We defined HIV virological 
suppression as plasma HIV RNA viral load less than 400 copies per mL after 6–18 months 
of combination antiretroviral therapy. We considered viral load of 400 copies per mL or 
more after 6–18 months of combination antiretroviral therapy as virological failure.31 We 
also assessed virological failure in three subgroups (400–1000 copies per mL, 1001–9999 
copies per mL, and ≥10 000 copies per mL). We defined HIV immunological response as a 
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CD4 count increase of more than 30% compared with baseline after 9–15 months of 
combination antiretroviral therapy. We categorised retention status as retention, death, 
treatment withdrawal, or loss to follow-up (>90 days since a missed schedule visit).
We compared these four outcomes in four co-infection status groups: HIV monoinfection 
(HBV negative, HCV negative), HIV and HBV co-infection (HBV positive, HCV negative), 
HIV and HCV co-infection (HBV negative, HCV positive), and triple infection (HBV 
positive, HCV positive). We analysed covariates including sex, age (18–24, 25–29, 30–34, 
35–39, 40–44, 45–54, and ≥55 years), self-reported mode of HIV transmission (blood 
transfusion or former plasma donor, injection drug use, sex with men who have sex with 
men, heterosexual sex), baseline CD4 count (<50, 50–199, 200–349, and ≥350 cells per µL), 
baseline alanine aminotransferase concentration (<40, 40–79, and ≥80 U/L), and baseline 
total bilirubin concentration (<17·1, ≥17·1 µmol/L).
HIV infection status was based on positive test results from two peripheral blood samples by 
HIV ELISA and confirmed by western blot. All HIV testing sites were certified by the 
National AIDS Reference Laboratory at China CDC. HBV chronic infection was defined by 
the presence in serum samples of HBsAg according to ELISA. We assessed serum HCV 
antibody positivity by second-generation or third-generation ELISA techniques; no 
information for HCV RNA testing was collected in the database.
Statistical analysis
We assessed characteristics by co-infection status with χ2 tests (for categorical data) and 
non-parametric Wilcoxon tests (for continuous data). We assessed all-cause mortality and 
non-injury-related mortality by co-infection status with Kaplan-Meier analysis. We used log-
rank tests to assess significance. We used Cox proportional hazard models to calculate 
unadjusted and adjusted hazard ratios (HRs) and 95% CIs. We tested deviations from the 
proportional hazard assumption by log-log survival plots. Because of the relation between 
HCV co-infection and injection drug use, for each multivariable analysis, we adjusted or 
stratified by transmission route (injection drug use or sexual contact).
We used logistic regression to estimate unadjusted and adjusted odds ratios (ORs) and 95% 
CIs for virological failure, immunological response, and treatment retention. As a sensitivity 
analysis for virological failure, we used two viral load cutoffs (>1000 and ≥10 000 copies 
per mL). We selected covariates a priori for inclusion in multivariable models on the basis of 
biological importance.27,31 We deemed a p value less than 0·05 as statistically significant for 
all analyses. We did the analyses with SAS (version 9.2).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for publication.
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Results
70 694 people with HIV started combination antiretroviral therapy between 2010 and 2011, 
36 833 of whom we excluded either because they lacked HBV or HCV testing results (n=35 
855), or because they had not started a standard initial treatment regimen (n=978). 33 861 
patients met eligibility criteria. 2958 (8·7%) participants had HBV co-infection, 6149 
(18·2%) had HCV co-infection, and 1114 (3·3%) had triple infection. Two-thirds of 
participants were men with a median age of 37 years (table 1). About two-thirds of 
participants were infected through heterosexual transmission and almost half received 
antiretroviral treatment at a county or lower level hospital. Median CD4 count at treatment 
initiation was 195 cells per µL and most patients received zidovudine, lamivudine, and 
nevirapine or efavirenz as the initial regimen (table 1). Patients with HCV or triple infection, 
compared with those with HBV or HIV monoinfection, were more likely to be male 
(p<0·001), to have been infected by injection drug use (p<0·001), and to have initiated 
antiretroviral treatment at a county or lower level hospital (p<0·001). Median CD4 cell 
counts at baseline were higher in patients with triple infection and HCV infection than in 
those with HBV or HIV monoinfection (table 1).
2054 participants died from any cause during 556 400 person-months of follow-up. Median 
follow-up was 15 months (IQR 12–23). Median follow-up for participants with HCV (14 
months) was slightly lower than that in the other three co-infection groups (15 months). The 
cumulative probability of all-cause death was 3·4% at 6 months, 5·0% at 12 months, and 
7·6% at 24 months. In univariable analyses, compared with monoinfection, people with 
triple infection had the highest risk of death, followed by those with HCV co-infection, and 
HBV co-infection (table 2, figure 1A). A multivariable analysis adjusting for all covariates 
(table 2, appendix) showed that patients with HIV, HBV, and HCV were more likely to die 
than were those with HIV only (p<0·0001), as were those with HIV and HCV (p<0·0001). 
Participants with HIV and HBV did not have a significantly higher risk of death than those 
with HIV only (p=0·51; table 2). When stratified by transmission route, we found much the 
same associations, although the association of HCV co-infection with all-cause death was 
not significant for patients who had contracted HIV through injection drug use (table 2).
After excluding 166 participants who died of injuries, 33 695 remained in the analysis of 
non-injury death. The cumulative probability of non-injury death at each point was similar 
but lower than all-cause death (figure 1B). The associations between co-infection and non-
injury death in univariable and multivariable analyses were consistent with the analyses of 
all-cause death (table 2).
23 991 participants had viral load test results. Viral suppression was rarest among people 
with triple infection (492 of 660; 74·5%), and more common among people with HCV and 
HIV (3023 of 3926; 77·0%), HIV and HBV (1873 of 2122; 88·3%), and HIV only (15 223 
of 17 283; 88·1%; figure 2A). 12·9% of people with triple infection had a viral load of 10 
000 copies per mL or more, compared with 11·9% of those with HCV–HIV co-infection, 
and 5·4% with HBV–HIV co-infection. In multivariable analysis, people with triple 
See Online for appendix
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infection were more likely to have virological failure than were those with monoinfection 
(figure 3). Patients co-infected with HCV were not significantly more likely to have 
virological failure. Virological failure occurred at much the same rate in participants co-
infected with HIV and HBV, and those with HIV only (figure 3). Sensitivity analyses with 
different cutoffs for virological failure showed much the same results (figure 3).
25 303 patients had CD4 cell count test results. An immunological response occurred in 427 
(59·8%) of 714 patients with triple infection, 2478 (60·1%) of 4125 with HIV and HCV, 
1652 (74·1%) of 2230 with HIV and HBV, and 13 400 (73·5%) of 18 234 with HIV only 
(figure 2B). Change in CD4 cell count did not differ significantly between hepatitis co-
infection groups and patients with HIV only (figure 3).
People with triple infection were most likely to be lost to follow-up, followed by those with 
HCV co-infection, those with HBV co-infection, and those with HIV only (figure 2C). In 
adjusted logistic regression analysis, non-retention in treatment was more likely in people 
with triple infection and HCV co-infection than in those with HIV infection only (figure 3). 
No significant difference occurred between those with HBV and HIV, and those with HIV 
only (figure 3).
Discussion
In this cohort of people being treated for HIV in China, 8·7% had HBV co-infection, 18·2% 
had HCV co-infection, and 3·3% had triple infection. Those with triple infection and HCV 
co-infection had a higher risk of death and not being retained in treatment. Triple infection 
also increased the risk of virological failure. Co-infection with HCV did not affect 
virological or immunological responses. Co-infection with HBV did not significantly affect 
any outcomes.
The prevalence of HBV co-infection in this study is lower than previously reported in Asia 
(14·6–21·7%),23,32 but higher than reported in the USA (4·5%).9 This difference is partly 
because of a greater proportion of men who have sex with men in previous studies. By 
contrast, the proportion of HCV co-infection in our study is higher than that previously 
reported in the Asia–Pacific region (7·2–10·4%).25,33 The predominate mode of HIV 
transmission in participants with HBV was heterosexual sex, which accords with other 
studies in Asia,32,33 but it was less common than reported in the USA and Europe.9,34 The 
primary mode of transmission of HIV among patients with HCV co-infection and triple 
infection was injection drug use, which occurred in much the same proportions as reported 
in the USA, Canada, and Europe.35,36 Patients infected from blood donation or transfusion 
were the largest known HIV-infected population in the early to mid-1990s in China.37 
However, few patients in our analysis were infected through this route, showing the benefits 
of blood donation screening policies. The prevalence of hepatitis co-infection varied by 
population characteristics in our study, and previous studies have reported variation by 
geographic location within China.25
Our findings support results from most previous studies, showing that people with HIV and 
HCV have shorter survival even after starting antiretroviral treatment.22,38,39 By contrast, 
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one report showed no significant effect of HCV, which might be because of a smaller 
number of deaths than in our study.25 Our findings also accord with previous studies 
showing no difference in survival between people with HIV and HBV, and those with HIV 
only,25,33 which could be related to the inclusion of lamivudine in the initial HIV treatment 
regimen.40
People with triple infection had significantly worse virological responses than those with 
HIV only, a finding which has not previously been well documented. We recorded no other 
differences in virological or immunological responses, which is consistent with most 
previous studies.19,20,24,25,32,38 One study suggested that HBV infection could increase HIV 
virological failure,23 but it was done in a single hospital with a high proportion of men who 
have sex with men so might not be generalisable.
Participants with triple infection or with HIV–HCV co-infection were less likely to be 
retained in treatment than were other participants. This finding is a concern, as maintenance 
of treatment and care is crucial to improve individual and public health outcomes.41 Low 
retention in these groups might, in part, be the result of them having a high proportion of 
injection drug users, who have a higher risk of leaving care and of death than other patients 
in China.41,42 However, other factors might also be involved. Additional research is needed 
to develop interventions aimed at increasing retention.
Our results should be interpreted within the study’s limitations. First, HBV infection was 
diagnosed by HBsAg testing, which only measures presence or absence of antigen. We did 
not measure biomarkers that represent HBV activity status, and thus we were unable to 
identify acute HBV infection or HBV stage. This shortcoming might mean some individuals 
with acute infection were classified as having chronic disease, leading to overestimation of 
chronic HBV infection. However, this bias is somewhat balanced by missing the diagnosis 
of occult HBV infection (undetectable HBsAg in serum with the presence of HBV DNA), 
with proportions of occult HBV infection ranging from 3% to 11% in people with HIV.43,44 
Second, HCV diagnosis was based on antibodies, not RNA. With the high prevalence of 
interleukin 28B genotype CC in Asia,45 patients who might have cleared the infections were 
included in the HCV group, overestimating the prevalence of HCV infection.20 Third, 
because of the little information for cause of death, we could not differentiate between non-
AIDS-related and AIDS-related deaths. Hepatitis-related liver-disease deaths are common in 
people with HIV, therefore we might have overestimated the effect of hepatitis on HIV 
progression. However, we excluded patients with injury-related deaths, partly removing the 
effect of non-AIDS deaths. Fourth, we could not control for other factors, such as 
socioeconomic status, tobacco and alcohol use, and time since diagnosis, because these data 
were not collected in the database. Fifth, injection drug use might be under-reported, leading 
to confounding related to misclassification of transmission mode. Finally, ascertainment of 
death was not linked with a centralised death registry, thus mortality might be 
underestimated.46
To the best of our knowledge, this is the first large, national cohort study to comprehensively 
assess survival, virological and immunological responses, and retention in care of people 
with HIV co-infected with HBV or HCV, or both (panel). Our findings emphasise the 
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importance of screening for viral hepatitis when individuals are identified as HIV positive. 
Moreover, effective management for viral hepatitis should be integrated into HIV treatment 
programmes, including effective treatment for triple infection and co-infection with HCV or 
HBV, and HBV vaccination for HBV-negative people with HIV to reduce HIV-related 
morbidity and mortality in regions in China where hepatitis is endemic. Long-term data are 
needed about the effect of hepatitis co-infection on HIV disease progression.
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Panel: Research in context
Systematic review
We searched Medline with the terms “HIV”, “HBV”, “HCV”, and “co-infection”. We 
found several studies that show that HIV can accelerate hepatitis-related liver diseases.
15,19
 By contrast, the effect of infection with hepatitis B virus (HBV) or hepatitis C virus 
(HCV) on HIV clinical progression, immunological response, and viral response has not 
been well established.20–22 Some studies have found no effect of hepatitis virus infection 
on viral and immunological response to combination antiretroviral therapy or mortality.25 
However, others have shown that HIV-HBV co-infection increases the risk of virological 
failure and death,23 although our findings in the present study do not support this. Our 
study results support previous findings that HIV and hepatitis C virus co-infection 
decreases survival.24 Very few data exist for the effect of triple viral infection. Our study 
suggests worse outcomes for those with triple infection compared with those with HIV 
alone.
Interpretation
These viruses share routes of transmission and many people with HIV are co-infected 
with HBV and HCV in China, particularly in injection drug users, sex workers, and men 
who have sex with men. Of an estimated 700 000 people with HIV in China about 10% 
also have HBV.47 A systematic review of methadone maintenance treatment clinics in 
China showed 4·6% of attendees had HCV–HIV co-infection.48 Our findings emphasise 
the importance of screening for viral hepatitis when individuals are diagnosed with HIV. 
Moreover, effective management of viral hepatitis should be integrated into HIV 
treatment programmes.
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Figure 1. Cumulative probability of death, by hepatitis virus infection status
(A) All-cause mortality and (B) non-injury mortality. HBV=hepatitis B virus. 
HCV=hepatitis C virus.
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Figure 2. Outcomes after 12 months of combination antiretroviral therapy
(A) Viral load response, (B) change of CD4 cell count, and (C) retention status. 
HBV=hepatitis B virus. HCV=hepatitis C virus.
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Figure 3. Multivariable analyses of association between hepatitis co-infection and outcomes
Controlled for age, sex, treatment centre, CD4 cell count, HIV transmission mode, and 
initial antiretroviral treatment regimens. *Includes death and stopping.
Zhang et al. Page 14
Lancet Infect Dis. Author manuscript; available in PMC 2018 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhang et al. Page 15
Ta
bl
e 
1
B
as
el
in
e 
ch
ar
ac
te
ris
tic
s
To
ta
l (n
=3
3 8
61
)
Tr
ip
le
 in
fe
ct
io
n
(n
=1
11
4)
H
C
V
–H
IV
 co
-
in
fe
ct
io
n(
n=
61
49
)
H
BV
–H
IV
 co
-
in
fe
ct
io
n 
(n
=2
95
8)
H
IV
 o
nl
y
(n
=2
3 6
40
)
A
ge
 a
t s
ta
rt 
of
 a
nt
ire
tro
v
ira
l t
he
ra
py
 (y
ea
rs)
37
 (3
1–
46
)
35
 (3
1–
40
)
36
 (3
2–
41
)
37
 (3
1–
46
)
38
 (3
0–
48
)
 
 
18
–2
4
21
35
 (6
·3%
)
33
 (3
·0%
)
18
8 
(3·
1%
)
18
0 
(6·
1%
)
17
34
 (7
·4%
)
 
 
25
–2
9
48
54
 (1
4·3
%)
14
6 
(13
·1%
)
69
9 
(11
·4%
)
43
9 
(14
·8%
)
35
70
 (1
5·1
%)
 
 
30
–3
4
63
54
 (1
8·8
%)
32
4 
(29
·1%
)
15
24
 (2
4·8
%)
57
9 
(19
·6%
)
39
27
 (1
6·6
%)
 
 
35
–3
9
65
37
 (1
9·3
%)
32
9 
(29
·5%
)
18
41
 (2
9·9
%)
50
6 
(17
·1%
)
38
61
 (1
6·3
%)
 
 
40
–4
4
46
69
 (1
3·8
%)
17
0 
(15
·3%
)
11
88
 (1
9·3
%)
40
2 
(13
·6%
)
29
09
 (1
2·3
%)
 
 
45
–5
4
48
87
 (1
4·4
%)
90
 (8
·0%
)
57
4 
(9·
3%
)
46
1 
(15
·6%
)
37
62
 (1
5·9
%)
 
 
≥5
5
44
25
 (1
3·1
%)
22
 (2
·0%
)
13
5 
(2·
2%
)
39
1 
(13
·2%
)
38
77
 (1
6·4
%)
Se
x
 
 
M
al
e
22
 5
34
 (6
6·6
%)
94
2 
(84
·6%
)
49
51
 (8
0·5
%)
20
64
 (6
9·8
%)
14
 5
77
 (6
1·7
%)
 
 
Fe
m
al
e
11
 3
27
 (3
3·4
%)
17
2 
(15
·4%
)
11
98
 (1
9·5
%)
89
4 
(30
·2%
)
90
63
 (3
8·3
%)
Tr
an
sm
iss
io
n 
m
od
e
 
 
B
lo
od
 tr
an
sf
us
io
n 
or
 p
re
v
io
us
 p
la
sm
a 
do
na
tio
n
41
8 
(1·
3%
)
14
 (1
·3%
)
16
8 
(2·
9%
)
43
 (1
·5%
)
19
3 
(0·
9%
)
 
 
In
jec
tio
n d
rug
 us
e
69
59
 (2
2·0
%)
80
3 
(74
·8%
)
44
57
 (7
5·9
%)
31
6 
(11
·3%
)
13
83
 (6
·3%
)
 
 
M
SM
31
59
 (1
0·0
%)
8 
(0·
8%
)
61
 (1
·0%
)
31
7 
(11
·4%
)
27
73
 (1
2·7
%)
 
 
H
et
er
os
ex
u
al
21
 1
28
 (6
6·7
%)
24
8 
(23
·1%
)
11
87
 (2
0·2
%)
21
13
 (7
5·8
%)
17
 5
80
 (8
0·1
%)
Ty
pe
 o
f t
re
at
m
en
t c
en
tre
 
 
In
fe
ct
io
us
 d
ise
as
e 
ho
sp
ita
l
23
56
 (7
·0%
)
53
 (4
·8%
)
37
0 
(6·
0%
)
19
9 
(6·
7%
)
17
34
 (7
·4%
)
 
 
Pr
ov
in
ci
al
 o
r p
re
fe
ct
ur
al
 h
os
pi
ta
l
11
 4
07
 (3
3·8
%)
31
3 
(28
·3%
)
20
17
 (3
3·0
%)
11
26
 (3
8·3
%)
79
51
 (3
3·8
%)
 
 
Ce
nt
er
 fo
r D
ise
as
e 
Co
nt
ro
l a
nd
 P
re
v
en
tio
n
51
45
 (1
5·3
%)
89
 (8
·0%
)
47
4 
(7·
8%
)
47
5 
(16
·2%
)
41
07
 (1
7·4
%)
 
 
Co
un
ty
 o
r l
ow
er
 le
v
el
 h
os
pi
ta
l
14
 8
09
 (4
3·9
%)
65
2 
(58
·9%
)
32
53
 (5
3·2
%)
11
42
 (3
8·8
%)
97
62
 (4
1·4
%)
B
as
el
in
e 
CD
4 
co
un
t (
ce
lls
 pe
r µ
L)
19
5 
(82
–2
83
)
22
3 
(11
0–
30
6)
21
6 
(11
8–
30
1)
17
8 
(58
–2
71
)
19
0 
(74
–2
78
)
 
 
≥3
50
26
10
 (7
·9%
)
13
5 
(12
·5%
)
77
3 
(12
·9%
)
18
0 
(6·
2%
)
15
22
 (6
·6%
)
 
 
20
0–
34
9
13
 5
47
 (4
0·9
%)
45
9 
(42
·5%
)
24
94
 (4
1·8
%)
11
00
 (3
8·0
%)
94
94
 (4
0·9
%)
 
 
50
–1
99
11
 0
54
 (3
3·4
%)
34
1 
(31
·6%
)
20
83
 (3
4·9
%)
96
7 
(33
·4%
)
76
63
 (3
3·0
%)
 
 
0–
49
59
27
 (1
7·8
%)
14
4 
(13
·4%
)
61
9 
(10
·4%
)
64
7 
(22
·4%
)
45
17
 (1
9·5
%)
Lancet Infect Dis. Author manuscript; available in PMC 2018 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhang et al. Page 16
To
ta
l (n
=3
3 8
61
)
Tr
ip
le
 in
fe
ct
io
n
(n
=1
11
4)
H
C
V
–H
IV
 co
-
in
fe
ct
io
n(
n=
61
49
)
H
BV
–H
IV
 co
-
in
fe
ct
io
n 
(n
=2
95
8)
H
IV
 o
nl
y
(n
=2
3 6
40
)
A
la
ni
ne
 a
m
in
ot
ra
ns
fe
ra
se
 c
on
ce
nt
ra
tio
n 
(U
/L
)
 
 
<
40
24
 3
58
 (7
2·6
%)
58
1 
(52
·7%
)
33
38
 (5
4·6
%)
19
75
 (6
7·4
%)
18
 4
64
 (7
8·9
%)
 
 
40
–7
9
67
68
 (2
0·2
%)
34
4 
(31
·2%
)
18
00
 (2
9·5
%)
71
1 
(24
·3%
)
39
13
 (1
6·7
%)
 
 
≥8
0
24
17
 (7
·2%
)
17
7 
(16
·1%
)
97
0 
(15
·9%
)
24
5 
(8·
4%
)
10
25
 (4
·4%
)
To
ta
l b
ili
ru
bi
n 
co
nc
en
tra
tio
n 
(µm
ol/
L)
 
 
<
17
·1
28
 2
71
 (8
7·0
%)
82
7 
(79
·4%
)
48
36
 (8
2·9
%)
24
10
 (8
3·9
%)
20
 1
98
 (8
8·8
%)
 
 
≥1
7·
1
42
33
 (1
3·0
%)
21
4 
(20
·6%
)
99
9 
(17
·1%
)
46
2 
(16
·1%
)
25
58
 (1
1·2
%)
In
iti
al
 a
nt
ire
tro
v
ira
l r
eg
im
en
 
 
A
ZT
+3
TC
+N
V
P/
EF
V
22
 3
40
 (6
6·0
%)
65
2 
(58
·5%
)
38
76
 (6
3·0
%)
16
46
 (5
5·7
%)
16
 1
66
 (6
8·4
%)
 
 
D
4T
+3
TC
+N
V
P/
EF
V
88
11
 (2
6·0
%)
28
6 
(25
·7%
)
14
80
 (2
4·1
%)
73
1 
(24
·7%
)
63
14
 (2
6·7
%)
 
 
TD
F+
3T
C+
N
V
P/
EF
V
27
10
 (8
·0%
)
17
6 
(15
·8%
)
79
3 
(12
·9%
)
58
1 
(19
·6%
)
11
60
 (4
·9%
)
D
at
a 
ar
e 
m
ed
ia
n 
(IQ
R)
 or
 n 
(%
). A
ll v
ar
ia
bl
es
 w
er
e 
sig
ni
fic
an
tly
 a
ss
oc
ia
te
d 
w
ith
 h
ep
at
iti
s c
o-
in
fe
ct
io
n 
gr
ou
ps
 (p
<0
·05
). H
BV
=h
ep
ati
tis
 B
 vi
rus
. H
CV
=h
ep
ati
tis
 C
 vi
rus
. M
SM
=m
en
 w
ho
 ha
v
e 
se
x
 w
ith
 m
en
. 
A
ZT
=z
id
ov
u
di
ne
. 3
TC
=l
am
iv
u
di
ne
. N
V
P=
ne
v
ira
pi
ne
. E
FV
=e
fa
v
ire
nz
. D
4T
=s
ta
v
u
di
ne
. T
D
F=
te
no
fo
v
ir.
Lancet Infect Dis. Author manuscript; available in PMC 2018 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhang et al. Page 17
Table 2
Associations between hepatitis co-infection and time to death
Triple infection HCV–HIV co-infection HBV–HIV co-infection HIV only
All-cause mortality (n=33 861)
Number of events 131 501 186 1236
Time on antiretroviral treatment (months) 17 892 96 680 49 007 392 821
Unadjusted HR (95% CI), p value 2·32 (1·94–2·77), <0·0001 1·62 (1·46–1·80), <0·0001 1·21 (1·03–1·41), 0·02 ··
HR adjusted by age and sex (95% CI), p 
value
2·49 (2·07–2·99), <0·0001 1·72 (1·54–1·92), <0·0001 1·20 (1·03–1·40), 0·02 ··
HR adjusted by all factors but not 
transmission mode (95% CI), p value
2·63 (2·16–3·20), <0·0001 2·03 (1·80–2·28), <0·0001 1·09 (0·92–1·29), 0·31 ··
HR adjusted by all factors and transmission 
mode (95% CI), p value
1·90 (1·53–2·37), <0·0001 1·46 (1·25–1·70), <0·0001 1·06 (0·89–1·26), 0·51 ··
HR adjusted by all factors, stratified by 
transmission mode (95% CI), p value 
Injection drug use
1·63 (1·23–2·17), 0·0008 1·21 (0·97–1·51), 0·09 0·97 (0·61–1·54), 0·91 ··
Sexual transmission 1·99 (1·31–3·02), 0·001 1·84 (1·47–2·29), <0·0001 1·04 (0·86–1·26), 0·71 ··
Non-injury mortality (n=33 695)
Number of events 117 450 174 1147
Time on antiretroviral treatment (months) 17 736 96 170 48 906 392 107
Unadjusted HR (95% CI), p value 2·25 (1·86–2·72), <0·0001 1·58 (1·41–1·76), <0·0001 1·22 (1·04–1·43), 0·02 ··
HR adjusted by age and sex (95% CI), p 
value
2·43 (2·00–2·95), <0·0001 1·68 (1·50–1·89), <0·0001 1·21 (1·03–1·42), 0·02 ··
HR adjusted by all factors but not 
transmission mode (95% CI), p value
2·57 (2·09–3·15), <0·0001 2·00 (1·77–2·26), <0·0001 1·09 (0·92–1·29), 0·34 ··
HR adjusted by all factors and transmission 
mode (95% CI), p value
1·94 (1·54–2·44), <0·0001 1·47 (1·25–1·73), <0·0001 1·06 (0·89–1·27), 0·51 ··
HR adjusted by all factors, stratified by 
transmission mode (95% CI), p value 
Injection drug use
1·68 (1·24–2·27), 0·001 1·25 (0·99–1·59), 0·06 0·96 (0·59–1·58), 0·88 ··
Sexual transmission 2·04 (1·33–3·13), 0·001 1·79 (1·42–2·26), <0·0001 1·06 (0·87–1·29), 0·57 ··
HBV=hepatitis B virus. HCV=hepatitis C virus. HR=hazard ratio.
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